Assertio Holdings, Inc. Class Action Lawsuit - ASRT

The filed complaint alleges that Assertio Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s reliance on Indocin products to boost its net income was unsustainable given the risk of generic competition; (ii) Assertio's acquisition of Spectrum Pharmaceuticals, Inc. and Spectrum’s injection asset, Rolvedon, was less valuable than Assertio had represented to investors; (iii) accordingly, Assertio had overstated the positive impact the sale of Indocin products and the acquisition were likely to have on the Company’s profitability; and (iv) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

In order to be eligible to join the ASRT class action lawsuit, you must have incurred a loss on shares of Assertio Holdings purchased during the class period listed above.

If you suffered a loss in Assertio Holdings during the relevant time frame or pursuant to the relevant offering(s), you have until March 5, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.